Saqib Islam was appointed Chief Executive Officer of SpringWorks Therapeutics in 2018. He was a founding member of the company’s executive team since its launch in 2017 and previously served as Chief Financial Officer and Chief Business Officer of the company. Prior to joining SpringWorks, Saqib was Chief Business Officer at Moderna Therapeutics, where he oversaw critical aspects of the company’s growth, including global strategic planning, corporate development and business development. Prior to Moderna, Saqib served as Executive Vice President, Chief Strategy and Portfolio Officer at Alexion Pharmaceuticals, executing the company’s corporate growth strategies and contributing to its assessment and management of global operations. Saqib has over 25 years of international business management experience and an extensive background in the healthcare banking sector, having held managing director positions in the investment banking divisions of Morgan Stanley and Credit Suisse Securities. He currently serves on the Board of Directors of ARYA Sciences Acquisition Corp III, Passage Bio (where he also serves as a member of its Audit Committee), and Silverback Therapeutics (where he also serves as a member of its Compensation Committee).
Saqib received his bachelor’s degree from McGill University, graduating as a Faculty and University Scholar, and a J.D. from Columbia Law School, where he was a Harlan Fiske Stone Scholar.
Badreddin Edris, Ph.D.
Chief Operating Officer
Dr. Badreddin Edris is responsible for corporate strategy, business development and capital formation. His professional experience spans private and public equity investing, company formation and operations, corporate and business development, and strategic and product planning in the biotechnology industry. Prior to joining SpringWorks Therapeutics, Badreddin was an investment and operating professional on the private equity team at OrbiMed, where he was involved in deal sourcing, evaluation and execution, as well as post-investment strategic and operational support for biotechnology companies across a range of therapeutic areas and stages of development. Badreddin also co-founded and held operating roles at two OrbiMed portfolio companies, Silverback Therapeutics (where he was Chief Business Officer) and Edgewise Therapeutics (where he was Chief Operating Officer). Before OrbiMed, Badreddin was a management consultant at Bain & Company, where he collaborated with global pharmaceutical and biotechnology companies on a range of strategic and operational projects.
Badreddin received his Ph.D. in genetics from Stanford University, where he was an NSF research fellow.
Chief Commercial Officer
Bhavesh Ashar is Chief Commercial Officer of SpringWorks Therapeutics and brings more than 20 years of global pharmaceutical and biotechnology experience to the role. Prior to joining SpringWorks, Bhavesh was Senior Vice President, General Manager of U.S. Oncology at Bayer Healthcare, where he served as Business Unit head for the U.S. Oncology franchise and was responsible for a broad portfolio in prostate, liver, colorectal, GIST, hematologic and tumor-agnostic biomarker driven cancers. Prior to joining Bayer in 2017, Bhavesh held roles of increasing responsibility at Sanofi Genzyme over a 15-year tenure, including Vice President, General Manager of U.S. Oncology and Vice President, Global Head of Transplant. Prior to Sanofi Genzyme, Bhavesh was a consultant with McKinsey & Company where he served clients in the biopharmaceutical space.
Bhavesh received an MBA from the University of Chicago and a B.S. in mathematics from the Imperial College in London.
Mike Burgess, M.B.Ch.B., Ph.D.
Head of Research and Development
Dr. Mike Burgess is Head of Research and Development (R&D) at SpringWorks Therapeutics. He brings over 20 years of experience building and leading R&D teams in oncology. Prior to joining SpringWorks, Mike was President of R&D at Turnstone Biologics where he led the buildout of a leading cancer immunotherapy R&D organization. Before Turnstone, Mike led the strategy and execution of translational medicine, early-stage clinical trials and clinical pharmacology across all therapeutic areas, including oncology, at Bristol-Myers Squibb. Before that, he held several different senior leadership positions at Hoffmann La-Roche, including Acting Global Head of Roche Pharma Research and Early Development (pRED) and Senior Vice President and Global Head of Oncology Research and Early Development. Prior to Roche, Mike was with Eli Lilly and Company, where he worked on early-stage oncology trials.
Mike received his medical degree (M.B.Ch.B.) and Ph.D. in molecular biology from the University of Bristol, UK and spent 10 years as a practicing physician in pediatrics and pediatric oncology.
Francis Perier, Jr.
Chief Financial Officer
Frank Perier is Chief Financial Officer of SpringWorks. He was previously Chief Financial Officer at Forest Laboratories, Inc. for ten years prior to the company’s acquisition by Actavis. Prior to joining Forest, Frank was with Bristol-Myers Squibb Company for approximately nine years, where he worked in corporate and operations finance capacities of increasing responsibilities, including Vice President of Finance and Operations Planning – Americas Medicines Group, the company’s largest business unit at that time. Before joining Bristol-Myers Squibb, he was an accounting and auditing partner at Deloitte, where he worked for about 15 years. Frank was a member of the Board of Directors of Concordia International, Inc., a specialty pharmaceutical company, until September 2018 where he served on the Audit and the Human Resources and Compensation Committees of the Company.
Frank received an MBA from the Stern School of Business, New York University and a B.S. in accountancy from Villanova University. He is a Certified Public Accountant (inactive) and a member of the New Jersey Society of Certified Public Accountants and the American Institute of Certified Public Accountants.
Chief People Officer
Daniel Pichl is an accomplished human resources executive who joined SpringWorks Therapeutics from Siemens Healthineers, USA where he was Senior Vice President, Head of Human Resources and Global HR Business Partner for the Ultrasound division. At Siemens, he had global responsibility for People Strategy, Employee Relations, Compensation & Benefits, Talent Acquisition, Talent & Performance Management, Leadership Development, and Learning. Prior to this role, he served as Vice President, Head of People & Leadership for the Americas region, and before that, he held positions of increasing responsibility at Siemens AG, Germany.
Daniel earned a Master of International Business degree from Macquarie University in Sydney, Australia, and a Master of Psychology degree from Ludwig-Maximilians-University in Munich, Germany.
Jens Renstrup, M.D., MBA
Chief Medical Officer
Dr. Jens Renstrup is responsible for developing and driving execution of the clinical development programs and oversees medical affairs. Prior to joining SpringWorks Therapeutics, Jens was Senior Vice President and Head of Global Medical Affairs at Alexion Pharmaceuticals, where he helped to shape the company’s early- to late-stage development pipeline and was instrumental in building out a leading medical affairs function. Prior to Alexion, Jens served as Vice President and Head of Global Medical Affairs at Glaxo Smith Kline Vaccines, where he developed the company’s medical strategy, which included evidence and engagement programs, and helped shape the development pipeline to support rapid drug applications in Europe, the United States and emerging markets. Jens also previously held progressive leadership positions at Merck & Co and started his career at IPSEN Scandinavia A/S.
Jens received a M.D. and specialist medical degree in anesthesiology and intensive care medicine from the University of Copenhagen, and an MBA from the Copenhagen Business School.
L. Mary Smith, Ph.D.
Chief Development Officer
Dr. Mary Smith is responsible for designing and running the clinical development programs. Prior to joining SpringWorks Therapeutics, Mary was the Executive Vice President of Gene Therapy at Bamboo Therapeutics, a wholly owned subsidiary of Pfizer where she led several key gene transfer programs for rare genetic diseases. Prior to joining Bamboo, Mary was Vice President of product development at United Therapeutics, with responsibility for biological development in oncology, as well as regenerative medicine and virology.
Mary earned a Ph.D. in microbiology/immunology from the University of New Hampshire and received her post-doctoral training at Emory University.
Herschel S. Weinstein, J.D.
General Counsel and Secretary
Herschel Weinstein is General Counsel of SpringWorks Therapeutics. He was previously Vice Chair of the Life Sciences Group at Lowenstein Sandler LLP where he represented life sciences companies in licensing, acquisitions, collaborations and joint venture transactions. Prior to his role at Lowenstein, Hershel was General Counsel of Forest Laboratories, Inc. for approximately eight years prior to the company’s acquisition by Actavis. While at Forest, Hershel established the in-house legal function, was responsible for the significant licensing, collaboration and acquisition transactions that the company executed, served as Corporate Secretary for all Corporate Governance and Board matters, and provided legal support to all functions of the organization. Before joining Forest, Hershel served as outside counsel for the company over many years as a partner at the law firm Dornbush Schaeffer Strongin & Venaglia, LLP.
Hershel received a J.D. from Harvard Law School and a B.A. from Brandeis University.
Swipe for More
Investigator-Initiated Research Terms and Conditions
All submitted proposals and related documents, including study concepts and protocols, shall be deemed Non-Conﬁdential. No conﬁdential relationship shall be established or implied by SpringWorks' acceptance of such materials.
SpringWorks shall have the right to retain any such materials. SpringWorks will only consider unsolicited IIR proposals submitted in writing by external investigators interested in studying SpringWorks drug candidates in therapeutic areas of interest. Support from SpringWorks, if any, will be granted on the basis of scientiﬁc merit. IIR budgets must be reasonable and appropriate for the proposed study.
Acceptance of the submission of a study concept or protocol does not constitute approval. SpringWorks reserves the right to decline support of a proposal any time after submission.
Following review by SpringWorks, the submitter will be notiﬁed as to whether the IIR proposal has been approved or denied, or if additional information is required. Approval of a study concept does not guarantee approval of a study protocol. SpringWorks shall have no obligation to give the reasons for its decisions.
SpringWorks support of an IIR will be subject to the execution of a written agreement which shall include terms aligned with the following principles:
Conduct of the Study. The IIR will be conducted in accordance with the ﬁnal protocol as approved by SpringWorks, International Conference on Harmonization Good Clinical Practice (ICH GCP) guidelines, and all applicable governmental laws, rules, and regulations. Also, if study drug is supplied by SpringWorks as part of an IIR, the Institution is expected to follow SpringWorks instructions such as those regarding proper handling of study drug (e.g., storage and handling, expiration of drug notices, drug disposal or destruction).
Sponsorship. The Institution, not SpringWorks, will be the sponsor of the IIR. The Institution, the Principal Investigator and the Institution staff will not represent to any third party, including IIR subjects, that SpringWorks is a sponsor.
Regulatory. The Institution will be solely responsible for any and all safety reporting and regulatory obligations associated with the conduct of the IIR, including, but not limited to, obtaining and maintaining an Investigational New Drug application (IND), if required.
IRB/IACUC Approval. The Principal Investigator will ensure that the IIR is approved by and subject to continuing oversight by an appropriate Institutional Review Board (IRB) or Institutional Animal Care and Use Committee (IACUC), and shall provide to SpringWorks a copy of such approval, and any extensions or renewals.
Informed Consent. For clinical studies, the Principal Investigator will obtain informed consent for each IIR subject in accordance with 21 Code of Federal Regulations Part 50 (unless an exemption under such part has been approved by the IRB and documentation of same can be provided), and will inform IIR subjects that SpringWorks is providing support for the IIR. SpringWorks shall have the right to review and comment on the informed consent form.
Registration of Study. For clinical studies, the Principal Investigator shall register the IIR at either (i)https://www.clinicaltrials.gov, or (ii) any other registry the requirements of which are consistent with the guidelines of the International Committee of Medical Journal Editors ("ICMJE") on trial registrations, in each case to the extent required by the ICMJE guidelines (as in effect at the time the IIR begins) in order for the IIR results to be eligible for publication in an ICMJE journal.
Reporting of Serious Adverse Events. For clinical studies utilizing a SpringWorks study drug product, within 24 hours of ﬁrst awareness of the event (immediately if the event is fatal or life-threatening), the Principal Investigator will report to SpringWorks by email any Serious Adverse Event ("SAE") that occurs during the SAE reporting period (as deﬁned in the agreement) in an IIR subject assigned to receive the SpringWorks study drug. The Principal Investigator will report to the appropriate Regulatory Authority (e.g., FDA) such SAEs using an FDA MEDWATCH form, and shall do so within the time frames set forth by FDA regulations. SAEs should be reported as soon as they are determined to meet the deﬁnition, even if complete information is not yet available.
Disclosure. SpringWorks will publicly disclose at its discretion, and in accordance with the information maintained in its internal business records, the name of the Institution and/or the Principal Investigator and certain information relating to the agreement including, but not limited to, any ﬁnancial and in-kind payments received under the agreement, the nature of the engagement and any other payment or service-related information as may be deemed appropriate by SpringWorks or as may be dictated by applicable law. Payments to the Institution for work done by speciﬁed individuals may reference both the Institution and the individual.